Eli Lilly Elects New Directors, Adjusts Officer Compensation
Ticker: LLY · Form: 8-K · Filed: Nov 19, 2024 · CIK: 59478
| Field | Detail |
|---|---|
| Company | Eli Lilly & Co (LLY) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: LLY
TL;DR
LLY board shakeup and pay adjustments announced today.
AI Summary
On November 19, 2024, Eli Lilly and Company (LLY) filed an 8-K detailing the election of new directors and changes in executive compensation. Specifically, the filing announced the election of new directors and adjustments to compensatory arrangements for certain officers, effective November 19, 2024.
Why It Matters
Changes in board composition and executive pay can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically carries a lower immediate risk compared to financial distress or major operational changes.
Key Players & Entities
- ELI LILLY & Co (company) — Filer
- 0000059478-24-000258 (document_id) — Accession Number
- 20241119 (date) — Filing Date
FAQ
Who were the new directors elected to the Eli Lilly board?
The filing states that new directors were elected, but does not name them in the provided text.
What specific changes were made to executive compensation arrangements?
The filing indicates adjustments to compensatory arrangements for certain officers, but the specific details of these adjustments are not provided in the excerpt.
What is the effective date of these changes?
The changes related to director elections and officer compensation are effective as of November 19, 2024.
What is the primary purpose of this 8-K filing?
This 8-K filing is primarily to report the departure of directors or certain officers, the election of directors, and changes to the compensatory arrangements of certain officers.
What is Eli Lilly's Standard Industrial Classification (SIC) code?
Eli Lilly's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 832 words · 3 min read · ~3 pages · Grade level 9.3 · Accepted 2024-11-19 16:49:17
Filing Documents
- lly-20241119.htm (8-K) — 52KB
- pr_november2024.htm (EX-99.1) — 8KB
- image_0.jpg (GRAPHIC) — 25KB
- image_1.jpg (GRAPHIC) — 86KB
- 0000059478-24-000258.txt ( ) — 435KB
- lly-20241119.xsd (EX-101.SCH) — 4KB
- lly-20241119_def.xml (EX-101.DEF) — 19KB
- lly-20241119_lab.xml (EX-101.LAB) — 37KB
- lly-20241119_pre.xml (EX-101.PRE) — 20KB
- lly-20241119_htm.xml (XML) — 10KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Eli Lilly and Company, dated November 19 , 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Anat Hakim Name: Anat Hakim Title: Executive Vice President, General Counsel and Secretary Date: November 19, 2024